Characteristics of Large Prospective Randomized Controlled Statin Trials Included in the Present Analysis

Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

Relationship Between Rates of ElevatedLiver Enzymes and % LDL-C Reduction

Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

Relationship Between Rates ofRhabdomyolysis and % LDL-C Reduction

Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

Rate of Elevated LiverEnzymes by Statin Dose Category

Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

Rate of Elevated LiverEnzymes by Lovastatin Dose Category

Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

Rate of Elevated LiverEnzymes by Simvastatin Dose Category

Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

Rate of Elevated LiverEnzymes by Atorvastatin Dose Category

Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

Characteristics of Large Prospective Randomized Controlled Statin Trials in Which Incident Cancer Rates Were

Reported, and Used for the Present Analysis

Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

Relationship Between Rates of Newly Diagnosed Cancer per 100,000 Person-Years and % LDL-C

Reduction

Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

Relationship Between Rates of Newly Diagnosed Cancer per 100,000 Person-Years and Absolute LDL-C

Reduct

Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

Relationship Between Rates of Newly Diagnosed Cancer per 100,000 Person-Years and Achieved LDL-C

Level

Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

Rate of Newly DiagnosedCancer by Statin Dose Category

Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

References

Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18